Hyperpyrexia in patients with COVID-19.

Area of Science:

• Infectious Diseases
• Neurology
• Critical Care Medicine

Background:

• Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, presents a global health challenge with unclear treatment and prevention strategies.
• Hyperpyrexia, defined as body temperature exceeding 106.7°F (41.5°C), is a critical condition not yet studied in COVID-19 patients.
• The pathophysiology, impact, and outcomes of hyperpyrexia in the context of COVID-19 remain largely unknown.

Purpose of the Study:

• To investigate the clinical features and outcomes of COVID-19 patients who developed hyperpyrexia during hospitalization.
• To explore the potential association between hyperpyrexia and mortality in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
• To propose potential mechanisms underlying hyperpyrexia development in COVID-19.

Main Methods:

• Retrospective case series analysis of six hospitalized COVID-19 patients who experienced hyperpyrexia.
• Clinical data collection focusing on the onset of hyperpyrexia and subsequent patient outcomes.
• Literature review to support proposed mechanisms for hyperpyrexia in SARS-CoV-2 infection.

Main Results:

• All six patients studied developed hyperpyrexia during their hospitalization for COVID-19.
• The onset of hyperpyrexia was followed shortly by expiration in all observed cases.
• Preliminary findings suggest hyperpyrexia is associated with adverse outcomes and increased mortality in COVID-19 patients.

Conclusions:

• Hyperpyrexia appears to be a significant negative prognostic indicator in patients with COVID-19.
• Potential causes for hyperpyrexia in COVID-19 may include SARS-CoV-2-related brain injury, dysregulated immune responses, or thrombotic events.
• Further research is crucial to understand the mechanisms linking hyperpyrexia and SARS-CoV-2 to inform treatment strategies and elucidate COVID-19 pathogenesis.